

(43) International Publication Date
19 November 2009 (19.11.2009)(10) International Publication Number
WO 2009/139076 A1

(51) International Patent Classification:

A61K 31/4164 (2006.01) **A61P 3/06** (2006.01)
A61K 31/4184 (2006.01) **C07D 233/58** (2006.01)
A61K 31/4188 (2006.01) **C07D 235/18** (2006.01)
A61K 31/428 (2006.01) **C07D 277/66** (2006.01)
A61K 31/4745 (2006.01) **C07D 471/04** (2006.01)
A61K 31/519 (2006.01) **C07D 487/04** (2006.01)
A61P 3/04 (2006.01) **C07D 513/04** (2006.01)

(21) International Application Number:

PCT/JP2008/059294

(22) International Filing Date:

14 May 2008 (14.05.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(71) **Applicant** (for all designated States except US): **OTSUKA PHARMACEUTICAL FACTORY, INC.** [JP/JP]; 115, Aza Kuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima, 7728601 (JP).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **NEAGU, Irina** [RO/US]; 3907 Hunters Glen, Plainsboro, New Jersey, 08536 (US). **OHLMEYER, Michael** [US/US]; 6 Beechtree Lane, Plainsboro, New Jersey, 08536 (US). **PARADKAR, Vidyadhar, M.** [US/US]; 3 Pine Ridge Drive, Somerville, New Jersey, 08876 (US). **SAIONZ, Kurt, W.** [US/US]; 508 Linden Place, Cranford, New Jersey, 07016 (US). **IWATA, Koushi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL FACTORY, INC., 115, Aza Kuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima, 7728601 (JP). **OKAMURA, Takashi** [JP/JP]; c/o OTSUKA PHARMACEUTICAL FACTORY, INC., 115, Aza

Kuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima, 7728601 (JP). **SHIBUTANI, Tadao** [JP/JP]; c/o OTSUKA PHARMACEUTICAL FACTORY, INC., 115, Aza Kuguhara, Tateiwa, Muya-cho, Naruto-shi, Tokushima, 7728601 (JP).


(74) **Agent: Saegusa & Partners**; Kitahama TNK Building, 1-7-1, Doshomachi, Chuo-ku Osaka-shi, Osaka, 5410045 (JP).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES

(1)

(57) **Abstract:** The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: wherein R¹, R², R³ and R⁴ are as defined in the specification.